Kavati A, Zhdanava M, Ortiz B, et al. - Researchers used a large sample of US real-world patients with chronic idiopathic urticaria (CIU) in order to evaluate omalizumab use and the long-term response in these patients. They used an electronic medical record system (2007–2018) to identify patients with CIU and ≥ 12 years old who were started on omalizumab (index date) and had ≥ 6 months of postindex data. Omalizumab use was reported. This study included 1,096 patients (mean age, 44.1 years; 74.7% women), observed for a mean of 19 months postindex. Findings revealed improved CIU control, course, and symptoms in correlation with the receipt of a mean of 15 omalizumab administrations over a mean of 14.2 months. These effects started to appear at 6 months and were evident through 24 months following omalizumab initiation and beyond.